Levin Capital Strategies’s Aerie Pharmaceuticals AERI Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2022
Q4 | – | Sell |
-1,125,395
| Closed | -$17M | – | 296 |
|
|
2022
Q3 | $17M | Sell |
1,125,395
-103,130
| -8% | -$1.2M | 2.31% | 10 |
|
|
2022
Q2 | $9.21M | Sell |
1,228,525
-207,351
| -14% | -$1.46M | 1.09% | 32 |
|
|
2022
Q1 | $13.1M | Buy |
1,435,876
+618,499
| +76% | +$4.77M | 1.26% | 27 |
|
|
2021
Q4 | $5.74M | Sell |
817,377
-556,165
| -40% | -$5.82M | 0.54% | 49 |
|
|
2021
Q3 | $15.7M | Buy |
1,373,542
+23,359
| +2% | +$341K | 1.56% | 21 |
|
|
2021
Q2 | $21.6M | Buy |
1,350,183
+436,299
| +48% | +$7.48M | 2.2% | 10 |
|
|
2021
Q1 | $16.3M | Buy |
913,884
+170,032
| +23% | +$2.94M | 1.74% | 18 |
|
|
2020
Q4 | $10M | Sell |
743,852
-603,131
| -45% | -$7.29M | 1.12% | 27 |
|
|
2020
Q3 | $15.9M | Sell |
1,346,983
-400,118
| -23% | -$4.87M | 2.07% | 10 |
|
|
2020
Q2 | $25.8M | Buy |
1,747,101
+246,344
| +16% | +$3.64M | 3.54% | 6 |
|
|
2020
Q1 | $20.3M | Sell |
1,500,757
-173,501
| -10% | -$3.29M | 3.27% | 7 |
|
|
2019
Q4 | $40.5M | Buy |
1,674,258
+483,652
| +41% | +$10M | 4.03% | 3 |
|
|
2019
Q3 | $22.9M | Buy |
1,190,606
+968,616
| +436% | +$22.2M | 2.53% | 12 |
|
|
2019
Q2 | $6.56M | Buy |
221,990
+216,990
| +4,340% | +$8.36M | 0.65% | 42 |
|
|
2019
Q1 | $237K | Buy |
+5,000
| New | +$220K | 0.03% | 159 |
|
Levin Capital Strategies's AERI Position: Q4 2022 in Review
Levin Capital Strategies sold out of Aerie Pharmaceuticals (AERI) in Q4 2022, closing a stake of 1,125,395 shares — an estimated $17M sold.
Levin Capital Strategies first reported a position in AERI in Q1 2019 and held it in 15 quarters. The position peaked at $40.5M in Q4 2019. 0 funds tracked by Wall St. Rank hold AERI as of Q4 2022.
- Levin Capital Strategies reported no remaining Aerie Pharmaceuticals position as of Q4 2022 after selling out during the quarter.
- Levin Capital Strategies sold 1,125,395 Aerie Pharmaceuticals shares in Q4 2022, an estimated $17M.
- Levin Capital Strategies first reported a position in Aerie Pharmaceuticals in Q1 2019 and held it in 15 quarters.
- Levin Capital Strategies's Aerie Pharmaceuticals position peaked at $40.5M in Q4 2019.
- 0 funds tracked by Wall St. Rank held Aerie Pharmaceuticals as of Q4 2022.
Based on Levin Capital Strategies's 13F filing for Q4 2022, filed 13 Feb 2023.